Kuwait armed forces responding to aerial attacks: statement
US strikes kill 3, wound 8 in southern Iran: Iranian state media
Messi to get 'special attention' from Spain, says de la Fuente
OPEC+ raises quotas again as Middle East calms
OPEC+ increases production quotas for August
Nepal PM marks 100 days with fast change and few words
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minima...